| Business Summary | | QLT
Inc.
engages
in
the
development
and
commercialization
of
proprietary
pharmaceutical
products
for
use
in
photodynamic
therapy,
an
emerging
field
of
medicine
utilizing
light-activated
drugs
in
the
treatment
of
disease.
QLT's
innovative
science
has
advanced
photodynamic
therapy
beyond
applications
in
cancer
towards
breakthrough
treatments
in
ophthalmology
and
autoimmune
disease. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | QLT
is
engaged
in
the
commercialization
and
development
of
proprietary
pharmaceutical
products
for
use
in
photodynamic
therapy,
an
emerging
field
of
medicine
utilizing
light-activated
drugs
in
the
treatment
of
disease.
For
the
six
months
ended
6/01,
revenues
totaled
C$54.2
million
up
from
C$12.5
million.
Net
income
before
U.S.
GAAP
totalled
C$19.3
million,
up
from
C$1.7
million.
Results
reflect
increased
revenues
from
Visudyne(TM)
and
the
absence
of
$5.3
million
in
development
costs. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | E. Duff Scott | Chairman | Julia Levy, Ph.D., 65 | Pres,
CEO, Director | Lee Pilson, 43 | Sr.
VP of Marketing | Mohammad Azab, M.D., 45 | Sr.
VP, Clinical Research and Medical Affairs | Edwin Levy, Ph.D., 60 | Sr.
VP, Corp. Devel. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|